

Press Release


IOL Chemicals and Pharmaceuticals Ltd

reports strong performance in Q1' FY21

Set up another Unit-VII to manufacture Metformin with additional capacity of 7200 MT per annum resulting to total installed capacity of 11,200 MT per annum

31st July, 2020, Ludhiana

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals today posted strong performance in the first quarter of FY 2020-21.



S. No	Particulars	₹ Crore	
		Quarter ended 30.06.2019 (Unaudited)	30.06.2020 (Audited)
1	Total Income from operations	496.12	465.91
2	EBIDTA	147.93	157.92
3	Net Profit for the period before tax (PBT)	131.02	146.74
4	Net Profit for the period after tax (PAT)	85.32	127.54
5	Earning per share (Basic & Diluted) ₹	15.00	22.30

The Company has successfully set up a new Unit-VII to manufacture Metformin with an installed capacity of 7,200 MT per annum. The Metformin is primarily used for the treatment of diabetes.

The Company, already has manufacturing facilities of Metformin (Unit-IV) with an existing installed capacity of 4,000 MT per annum. With the installation of Unit VII, the total manufacturing capacity of Metformin has now increased by about 3 folds at 11,200 MT per annum as compared to existing capacity.

The new manufacturing Unit-VII has been set up with the capex of about Rs 28 Crore, which has been funded fully through internal accruals only.

The new manufacturing Unit-VII has been established at the existing plant site of the Company at Barnala.

Mr Vijay Garg, Joint Managing Director said, we are very delighted with our continued strong operational performance during the first quarter of the FY 2021 in spite of difficult period of pandemic Covid-19.

He also added: that the Company has successfully set up another Unit VII to manufacture the Metformin with an installed capacity of 7,200 MT per annum to cater the growing demand. The Metformin is a well-established product of the Company in our bulk drug division.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange (Code: IOLCP) and Bombay Stock Exchange (Code: 524164) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico,

Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.